Clinical effect of Zhengyuan capsules combined with AP regimen for advanced lung adenocarcinoma
Objective To observe the clinical effect of Zhengyuan capsules combined with AP regimen(pemetrexed plus cisplatin)for advanced lung adenocarcinoma(LUAD).Methods Eighty patients with advanced LUAD treated in our hos-pital from February 2019 to February 2022 were enrolled,and they were randomly assigned into treatment group(n=40)and control group(n=40).All patients were managed by AP regimen,and those in treatment group were additionally treated with Zhengyuan capsules.The treatment continued for 4 courses(1 course for 3 weeks),aiming to compare levels of tumor markers(cytokeratin19 fragment21-1[CYFRA 21-1],carcinoembryonic antigen[CEA],carbohydrate antigen 125[CA125]),immune function indexes(CD4+,CD8+,natural killer[NK]cells),Karnofsky Performance Status(KPS)scores,side effects rates,as well as survival rate of 1-year follow-up.The curative effect was assessed.Results The remission rate of solid tumor in the treatment group was significantly higher than that in the control group(47.50%[19/40]vs 25.00%[10/40],P<0.05).After treatment,the levels of CYFRA21-1,CEA,CA125 in groups were significantly decreased(P<0.05),which decreased notably in the treatment group compared with the control group(P<0.05).After treatment,the levels of CD4+,NK cells in the treatment group were significantly increased(P<0.05),but which were significantly higher than those in the control group(P<0.05).The levels of CD4+,NK cells in the control group were significantly decreased(P<0.05).KPS score in groups after treatment was significantly increased(P<0.05),the increase in the treatment group was more prevalent compared to the control group(P<0.05).The progression-free survival time(PFS)in the treatment group was significantly longer than that in the control group([14.03±4.38]months vs[10.48±4.52]months,P<0.05).The log-rank test showed that the overall survival rate in the treatment group during follow-up was significantly higher than that in the control group(60.00%[24/40]vs 25.00%[10/40],P<0.05).Conclusion Zhengyuan capsules combined with AP regimen has significant therapeutic effects for patients with advanced LUAD,which can improve immune function and quality of life,reduce tumor marker levels,and prolong survival time,decrease side effects.
Lung adenocarcinomaAdvanced stageTraditional Chinese medicine therapyTumor markerImmune function
NETL
NSTL
万方数据
